Skip to main content

Table 1 Demographic and baseline characteristics (all treatment groups combined)

From: Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis

Characteristic LEI > 0
(N = 403)
LDI-B > 0
(N = 155)
Integrated analysis set
(N = 679)
Age, mean years (SD)a 51.2 (11.8) 47.8 (12.1) 51.0 (11.9)
Gender, n (%)
 Male 166 (41.2) 70 (45.2) 310 (45.7)
Race, n (%)a
 White 379 (94.0) 142 (91.6) 629 (92.8)
 Black or African American 1 (0.2) 0 (0.0) 3 (0.4)
 Asian 16 (4.0) 12 (7.7) 33 (4.9)
 Other/multiple 7 (1.7) 1 (0.6) 13 (1.9)
BMI, kg/m2, mean (SD)a 31.2 (7.8) 29.9 (7.3) 30.2 (7.3)
cDMARD experience, n (%) 231 (57.3) 96 (61.9) 385 (56.7)
MTX at baseline, n (%) 192 (47.6) 81 (52.3) 318 (46.8)
Time since PsA onset, mean years (SD) 11.0 (8.8) 9.7 (8.0) 11.0 (9.3)
Active PSO with BSA ≥ 3%, n (%)a 241 (65.7) 105 (74.5) 402 (65.4)
Tender joint count (68 joints), mean (SD)a 25.2 (15.5) 22.2 (13.5) 22.0 (14.9)
Swollen joint count (66 joints), mean (SD)a 12.5 (9.1) 15.2 (11.3) 11.9 (9.1)
Current enthesitis, n (%)a 403 (100.0) 108 (69.7) 403 (59.7)
Current dactylitis, n (%)a 108 (26.8) 155 (100.0) 155 (22.9)
Leeds Enthesitis Index, mean (SD)a,b 2.9 (1.6) 3.1 (1.6) 2.9 (1.6)
Leeds Dactylitis Index-Basic, mean (SD)a,c 58.2 (72.0) 56.4 (68.3) 56.4 (68.3)
  1. Abbreviations: BSA body surface area, BMI body mass index, cDMARD conventional disease-modifying antirheumatic drugs, LDI-B Leeds Dactylitis Index-Basic, LEI Leeds Enthesitis Index, MTX methotrexate, N population size, n number in group, PsA psoriatic arthritis, PSO psoriasis, SD standard deviation
  2. aThere are patients with missing baseline information in some groups; the denominator of a particular baseline measure is the number of patients with non-missing baseline measures
  3. bSummarized by patients with baseline enthesitis, defined as LEI score > 0
  4. cSummarized by patients with baseline dactylitis, defined as LDI-B score > 0
\